Brief: FDA Lifts Clinical Hold On Nuz-001
06/10/2025 07:35
Oct 6 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX: FDA LIFTS CLINICAL HOLD ON NUZ-001 NEURIZON THERAPEUTICS LTD: CLEARS WAY FOR ENTRY INTO HEALEY ALS PLATFORM TRIAL EXPECTED TO COMMENCE IN Q4 CY2025 Source text: ID:nPn1R427xa Further company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility